80 results found. Viewing page 1 of 8. Go to page 1 2  . . . 7 8   Next

    Biocept and Miraca Life Sciences Enter Into Marketing Agreement to Expand Target Selector Testing in the United States

    MLS to market Biocept’s proprietary liquid biopsy testing platform in key sales territories, with potential to expand the agreement in the future SAN DIEGO (October 3, 2017) – Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that ...

    Continue Reading

    Renflexis™ Is Commercially Available from Inform Diagnostics

    IRVING, Texas, January 19, 2018 — Inform Diagnostics, formerly Miraca Life Sciences, announced today that therapeutic drug monitoring is commercially available for Renflexis (infliximab-abda), a biosimilar of Remicade® (infliximab). Since launching the InformTx™ therapeutic drug monitoring (TDM) services in June 2016, the company has expanded its TDM testing to now eight biologic ...

    Continue Reading

    Miraca Life Sciences Announces Company Name Change to Inform Diagnostics

    IRVING, Texas, January 8, 2018 — Miraca Life Sciences announced today that it has changed its name to Inform Diagnostics effective immediately. The company was acquired in November by Avista Capital Partners from previous owner Miraca Holdings. The name Inform Diagnostics and new logo were chosen to highlight the company’s focus on providing pathology and diagnostic capabilities that ...

    Continue Reading

    Avista Capital Partners Completes Acquisition of Miraca Life Sciences

    IRVING, Texas and NEW YORK, Nov. 20, 2017 — Avista Capital Partners (“Avista”), a leading private equity firm, today announced the completion of its acquisition of Miraca Life Sciences (“MLS” or the “Company”) from Miraca Holdings Inc. Continue reading the press release at the Avista website.

    Continue Reading

    Renflexis™ is Latest Addition to Therapeutic Drug Monitoring by Miraca Life Sciences

    IRVING, Texas, October 16, 2017 — Miraca Life Sciences, the largest U.S. independent anatomic pathology laboratory, continues to expand in clinical pathology: its InformTx™ therapeutic drug monitoring (TDM) has begun the validation process for Renflexis™ (infliximab-abda), a biosimilar of Remicade® (infliximab). Testing will be commercially available in early November. Since ...

    Continue Reading

    Biocept and Miraca Life Sciences Enter Into Marketing Agreement to Expand Target Selector Testing in the United States

    MLS to market Biocept’s proprietary liquid biopsy testing platform in key sales territories, with potential to expand the agreement in the future SAN DIEGO (October 3, 2017) – Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that ...

    Continue Reading

    Avista Capital Partners to Acquire Miraca Life Sciences

    IRVING, TX, NEW YORK, NY, and TOKYO, September 22, 2017 – Avista Capital Partners (“Avista”), a leading private equity firm, and Miraca Holdings Inc. (“MHD”) announced today that Avista has signed a definitive agreement to acquire Miraca Life Sciences (“MLS” or “the Company”), a wholly-owned subsidiary of Miraca Holdings Inc. Continue reading ...

    Continue Reading

    Miraca Research News: Philips receives FDA clearance to market Philips IntelliSite Pathology Solution for primary diagnostic use in the US

    Pathologists at Inform Diagnostics contributed significantly in the development of a new product from Philips, the IntelliSite Pathology Solution. As one of four clinical study sites, Inform Diagnostics participated in “one of the largest studies ever conducted to directly compare the use of digital pathology to optical microscopes.” At Inform Diagnostics, participation in the Philips ...

    Continue Reading

    Ten Research Projects from Miraca Life Sciences Accepted for DDW Conference

    IRVING, Texas, April 12, 2017 — Ten research projects from the GI pathologists at Inform Diagnostics, the nation’s largest independent anatomic pathology lab, have been accepted for presentation at the Digestive Disease Week® conference (DDW), which will be held May 6–9 in Chicago. DDW is the world’s largest gathering of physicians, researchers and industry in the ...

    Continue Reading

    Simponi® is Sixth Drug in InformTx™ Therapeutic Drug Monitoring Service from Miraca Life Sciences

    IRVING, Texas, March 28, 2017 — Inform Diagnostics, the largest U.S. independent anatomic pathology laboratory, continues to expand its InformTx™ therapeutic drug monitoring (TDM) capabilities, now testing for Simponi (golimumab) as well as patient-developed antibodies to Simponi. This is the first TDM assay available in the United States for Simponi. With this addition, Inform ...

    Continue Reading
80 results found. Viewing page 1 of 8. Go to page 1 2  . . . 7 8   Next